ArticlePsoriasis (Auckland, N.Z.)2018
The Physician Global Assessment and Body Surface Area composite tool is a simple alternative to the Psoriasis Area and Severity Index for assessment of psoriasis: post hoc analysis from PRISTINE and PRESTA.
Article in Psoriasis (Auckland, N.Z.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A randomized, open-label, two-period study to evaluate the safety and efficacy of etanercept on skin and joint disease in psoriasis subjects with psoriatic arthritis
A Randomized, Double-Blind Trial Assessing the Efficacy and Safety of Etanercept 50 mg Twice Weekly and Etanercept 50 mg Once Weekly for the Treatment of Moderate to Severe Psoriasis
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Mind-Body Interventions as Alternative and Complementary Therapies for Psoriasis: A Systematic Review of the English Literature.Medicina (Kaunas, Lithuania) · 2021Pooled it
- Baseline imaging for determining infarct core in patients with acute ischemic stroke: noncontrast computed tomography vs computed tomography perfusion.Neuroradiology · 2026Article
- Real-World Effectiveness and Safety of Tapinarof 1% Cream in Psoriasis: An Observational Study From Bangladesh.Cureus · 2026Article
- Best Responders and Super-Responders to Calcipotriol and Betamethasone Dipropionate PAD-Cream: A Post Hoc Pooled Analysis of Two Phase 3 Trials.Dermatology and therapy · 2025Article
- Article
- Article
- Impact of Alcohol Consumption, Smoking, and Diet on the Severity of Plaque Psoriasis: A Comprehensive Assessment using Clinical Scales and Quality of Life Measures.Medical science monitor : international medical journal of experimental and clinical research · 2023Article
- Development of Psoriasis Assessment Tools Among Patients in the CorEvitas Psoriasis Registry.Journal of psoriasis and psoriatic arthritis · 2023Article
- Outcome measures in psoriatic arthritis: Where next?Musculoskeletal care · 2022Review
- Measurement of Body Surface Area for Psoriasis Using U-net Models.Computational and mathematical methods in medicine · 2022Article
- Article
- Measuring Outcomes in Psoriatic Arthritis.Arthritis care & research · 2020Review
- Product of Investigator Global Assessment and Body Surface Area (IGAxBSA): A practice-friendly alternative to the Eczema Area and Severity Index to assess atopic dermatitis severity in children.Journal of the American Academy of Dermatology · 2020Article
- Personalized medicine-concepts, technologies, and applications in inflammatory skin diseases.APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe product of Physician Global Assessment and Body Surface Area (PGA × BSA) is a new outcome measure for psoriasis severity and response to therapy. The objective of this study was to evaluate PGA × BSA as an alternative to Psoriasis Area and Severity Index (PASI) for psoriasis assessments.
methodsThe relationship between PASI and PGA × BSA was assessed in a post hoc analysis of pooled data from the PRISTINE (NCT00663052) and PRESTA (NCT00245960) trials in patients with moderate-to-severe psoriasis who received etanercept 50 mg/week. Data were analyzed using Spearman and intra-class correlation coefficients, effect sizes, scatterplots, Bland-Altman plots, and Kappa statistics.
resultsSpearman correlations at baseline, week 12, and week 24 were strong for PGA × BSA versus PASI (
conclusionPGA × BSA has advantages over PASI for measuring moderate-to-severe psoriasis; it is intuitive, sensitive, and easy to use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.